The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer

Resistance to endocrine therapy is common among breast cancer patients with estrogen receptor alpha-positive (ER+) tumors and limits the success of this therapeutic strategy. While the mechanisms that regulate endocrine responsiveness and cell fate are not fully understood, interferon regulatory factor-1 (IRF1) is strongly implicated as a key regulatory node in the underlying signaling network. IRF1 is a tumor suppressor that mediates cell fate by facilitating apoptosis and can do so with or without functional p53. Expression of IRF1 is downregulated in endocrine-resistant breast cancer cells, protecting these cells from IRF1-induced inhibition of proliferation and/or induction of cell death. Nonetheless, when IRF1 expression is induced following IFNγ treatment, antiestrogen sensitivity is restored by a process that includes the inhibition of prosurvival BCL2 family members and caspase activation. These data suggest that a combination of endocrine therapy and compounds that effectively induce IRF1 expression may be useful for the treatment of many ER+ breast cancers. By understanding IRF1 signaling in the context of endocrine responsiveness, we may be able to develop novel therapeutic strategies and better predict how patients will respond to endocrine therapy.

[1]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Shao-Chun Wang,et al.  Overcoming resistance to fulvestrant (ICI182,780) by Downregulating the c‐ABL Proto‐Oncogene in breast cancer , 2011, Molecular carcinogenesis.

[3]  Robert Clarke,et al.  Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. , 2005, Vitamins and hormones.

[4]  R. Friedman,et al.  Deregulated expression of interferon regulatory factor-1 in oncogene-transformed mouse fibroblasts. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[5]  K. Becker,et al.  NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[6]  N. Satoh,et al.  Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. , 1996, Gastroenterology.

[7]  Robert Clarke,et al.  Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. , 2005, Carcinogenesis.

[8]  R. Dummer,et al.  Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. O'Malley,et al.  HER2/neu in systemic therapy for women with breast cancer: a systematic review , 2008, Breast Cancer Research and Treatment.

[10]  N. López-Bigas,et al.  Biological reprogramming in acquired resistance to endocrine therapy of breast cancer , 2010, Oncogene.

[11]  T. Taniguchi,et al.  Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system , 1994, Molecular and cellular biology.

[12]  Robert Clarke,et al.  The nuclear factor κB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)–induced apoptosis in antiestrogen-resistant breast cancer cells , 2005 .

[13]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Jung-whan Kim,et al.  IFN‐γ/IRF‐1‐induced p27 kip1 down‐regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer , 2005 .

[15]  al. et,et al.  Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia , 1993, Science.

[16]  O. Delattre,et al.  IFN-β induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7 , 2000, Oncogene.

[17]  G. Doherty,et al.  The role of interferon regulatory factor-1 and interferon regulatory factor-2 in IFN-gamma growth inhibition of human breast carcinoma cell lines. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[18]  Y. Rubinstein,et al.  Interferon regulatory factor‐1 is a major regulator of epidermal growth factor receptor gene expression , 1998, FEBS letters.

[19]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[20]  Wei Zhang,et al.  Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-γ induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression , 2003, Oncogene.

[21]  T. Taniguchi,et al.  The IRF family transcription factors in immunity and oncogenesis. , 2008, Annual review of immunology.

[22]  R. Clarke,et al.  The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines. , 2007, Cancer genetics and cytogenetics.

[23]  R. Pine.  Convergence of TNFα and IFNγ signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/κB promoter element , 1997 .

[24]  J. Yee,et al.  The IFN Regulatory Factor Family Participates in Regulation of Fas Ligand Gene Expression in T Cells , 2000, The Journal of Immunology.

[25]  T. Taniguchi,et al.  Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity , 1997, Oncogene.

[26]  J. Gralow.  Optimizing the treatment of metastatic breast cancer , 2005, Breast Cancer Research and Treatment.

[27]  S. Teichmann,et al.  Tight Regulation of Unstructured Proteins: From Transcript Synthesis to Protein Degradation , 2008, Science.

[28]  P. Donahoe,et al.  Mullerian Inhibiting Substance Promotes Interferon γ-induced Gene Expression and Apoptosis in Breast Cancer Cells* , 2003, Journal of Biological Chemistry.

[29]  G. Colucci,et al.  Molecularly targeted endocrine therapies for breast cancer. , 2010, Cancer treatment reviews.

[30]  K. Ball,et al.  Intracellular Activation of Interferon Regulatory Factor-1 by Nanobodies to the Multifunctional (Mf1) Domain* , 2010, The Journal of Biological Chemistry.

[31]  R. Clarke,et al.  Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer , 2010, Breast Cancer Research and Treatment.

[32]  V. Landré,et al.  Docking-dependent Ubiquitination of the Interferon Regulatory Factor-1 Tumor Suppressor Protein by the Ubiquitin Ligase CHIP* , 2010, The Journal of Biological Chemistry.

[33]  M. Lynch,et al.  Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen. , 1987, British Journal of Cancer.

[34]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[35]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. , 2001, The Journal of clinical investigation.

[36]  A. Nicolini,et al.  Cytokines in breast cancer. , 2006, Cytokine & growth factor reviews.

[37]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[38]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[39]  G. Doherty,et al.  Interferon Regulatory Factor Expression in Human Breast Cancer , 2001, Annals of surgery.

[40]  Minetta C. Liu,et al.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling , 2003, Oncogene.

[41]  H. Hauser,et al.  Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis , 1999, Oncogene.

[42]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[43]  T. Taniguchi,et al.  Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 , 1994, Cell.

[44]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[45]  R. Schreiber,et al.  Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.

[46]  D. Harrison,et al.  Altered DNA repair and dysregulation of p53 in IRF‐1 null hepatocytes , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  Jung-whan Kim,et al.  IFN-gamma/IRF-1-induced p27kip1 down-regulates telomerase activity and human telomerase reverse transcriptase expression in human cervical cancer. , 2005, FEBS letters.

[48]  R. Clarke,et al.  BCL2 and CASP8 regulation by NF‐κB differentially affect mitochondrial function and cell fate in antiestrogen‐sensitive and ‐resistant breast cancer cells , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[49]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[50]  D. Schaid,et al.  Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Sahin,et al.  Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion , 2005, Molecular Cancer.

[52]  T. Taniguchi,et al.  Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage , 1996, Nature.

[53]  Takashi Miyata,et al.  Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes , 1989, Cell.

[54]  Hyun Seok Song,et al.  Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma. , 2006, International journal of oncology.

[55]  Borivoj Vojtesek,et al.  A Multiprotein Binding Interface in an Intrinsically Disordered Region of the Tumor Suppressor Protein Interferon Regulatory Factor-1* , 2011, The Journal of Biological Chemistry.

[56]  S. Pattingre,et al.  Bcl-2 inhibition of autophagy: a new route to cancer? , 2006, Cancer research.

[57]  S. Perea,et al.  Activation of the Human p27Kip1 Promoter by IFNα 2b , 2000 .

[58]  R. Clarke,et al.  Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant) , 2004, Cancer Research.

[59]  Lothar Hennighausen,et al.  Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. , 2010, Neoplasia.

[60]  G. Romeo,et al.  IRF-1 as a negative regulator of cell proliferation. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[61]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[62]  Meng Li,et al.  MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways , 2011, Oncogene.

[63]  T. Taniguchi,et al.  An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes , 1995, Nature.

[64]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[65]  Å. Borg,et al.  Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors , 2006, International journal of cancer.

[66]  Shin Namiki,et al.  IRF‐1 mediates upregulation of LMP7 by IFN‐γ and concerted expression of immunosubunits of the proteasome , 2005, FEBS letters.

[67]  K. Suk,et al.  Interferon gamma (IFNgamma ) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. , 2001, The Journal of biological chemistry.

[68]  T. Chambers,et al.  Pegylated IFN-α sensitizes melanoma cells to chemotherapy and causes premature senescence in endothelial cells by IRF-1-mediated signaling , 2010, Cell Death and Disease.

[69]  T. Taniguchi,et al.  Absence of the type I IFN system in EC cells: Transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated , 1990, Cell.

[70]  Y. Liu,et al.  Interferon regulatory factor-1-induced apoptosis mediated by a ligand-independent fas-associated death domain pathway in breast cancer cells , 2007, Oncogene.

[71]  M. Żylicz,et al.  Cooperative Regulation of the Interferon Regulatory Factor-1 Tumor Suppressor Protein by Core Components of the Molecular Chaperone Machinery* , 2009, The Journal of Biological Chemistry.

[72]  N. Brünner,et al.  Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). , 2002, Cancer research.

[73]  C. Knabbe,et al.  TGF‐Beta Signaling in Breast Cancer , 2006, Annals of the New York Academy of Sciences.

[74]  A. Howell,et al.  Evaluation of the current knowledge limitations in breast cancer research: a gap analysis , 2008, Breast Cancer Research.

[75]  T. Taniguchi,et al.  Functionally inactivating point mutation in the tumor‐suppressor IRF‐1 gene identified in human gastric cancer , 1998, International journal of cancer.

[76]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  T. Taniguchi,et al.  Interferon regulatory factor family of transcription factors and regulation of oncogenesis , 2008, Cancer science.

[78]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[79]  Robert Clarke,et al.  Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays. , 2006, International journal of oncology.

[80]  K. Ball,et al.  Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation. , 2009, Cellular signalling.

[81]  T. Taniguchi,et al.  IRF family of transcription factors as regulators of host defense. , 2001, Annual review of immunology.

[82]  P. Donahoe,et al.  Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells. , 2003, Journal of Biological Chemistry.

[83]  T. Taniguchi,et al.  Activation of IFN-beta element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. , 1991, Nucleic acids research.

[84]  R. Clarke,et al.  IFNγ Restores Breast Cancer Sensitivity to Fulvestrant by Regulating STAT1, IFN Regulatory Factor 1, NF-κB, BCL2 Family Members, and Signaling to Caspase-Dependent Apoptosis , 2010, Molecular Cancer Therapeutics.

[85]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[86]  A. Howell.  Fulvestrant ('Faslodex'): current and future role in breast cancer management. , 2006, Critical reviews in oncology/hematology.

[87]  Michelle L Bowie,et al.  Interferon-regulatory factor-1 is critical for tamoxifen-mediated apoptosis in human mammary epithelial cells , 2004, Oncogene.

[88]  Simon C Watkins,et al.  Ectopic Expression of Interferon Regulatory Factor-1 Promotes Human Breast Cancer Cell Death and Results in Reduced Expression of Survivin , 2004, Cancer Research.

[89]  K. Schulze-Osthoff,et al.  New Approaches and Therapeutics Targeting Apoptosis in Disease , 2005, Pharmacological Reviews.

[90]  J. Hiscott,et al.  Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins , 1997, Oncogene.

[91]  R. Pine.  Convergence of TNFalpha and IFNgamma signalling pathways through synergistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/kappaB promoter element. , 1997, Nucleic acids research.

[92]  J. Ward.  Duration of adjuvant endocrine therapy of breast cancer: how much is enough? , 2010, Current opinion in obstetrics & gynecology.

[93]  R. Clarke,et al.  Cellular and molecular pharmacology of antiestrogen action and resistance. , 2001, Pharmacological reviews.

[94]  C. Streuli,et al.  Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer , 2009, Breast Cancer Research.

[95]  J. Hiscott,et al.  A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity , 2004, Molecular and Cellular Biochemistry.

[96]  H. Yokosawa,et al.  Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. , 2000, European journal of biochemistry.

[97]  N. Parajuli,et al.  Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs , 2009, In Vitro Cellular & Developmental Biology - Animal.

[98]  P. Ferrari,et al.  Cytokines in the management of high risk or advanced breast cancer: an update and expectation. , 2009, Current cancer drug targets.

[99]  S. Mulero-Navarro,et al.  Resveratrol‐induced apoptosis in MCF‐7 human breast cancer cells involves a caspase‐independent mechanism with downregulation of Bcl‐2 and NF‐κB , 2005, International journal of cancer.

[100]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  Timothy R Billiar,et al.  IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo , 2004, Oncogene.